Herpes zoster as a risk factor for stroke and TIA
A retrospective cohort study in the UK
Citation Manager Formats
Make Comment
See Comments
This article has corrections. Please see:
- Herpes zoster as a risk factor for stroke and TIA: A retrospective cohort study in the UK - June 17, 2014
- EDITORIAL EXPRESSION OF CONCERN: Herpes zoster as a risk factor for stroke and TIA: A retrospective cohort study in the UK - February 05, 2014
- Herpes zoster as a risk factor for stroke and TIA - July 08, 2014

Article Information
- Received June 6, 2013
- Accepted in final form October 8, 2013
- First Published January 2, 2014.
Article Versions
- Previous version (January 2, 2014 - 13:01).
- Previous version (January 8, 2014 - 13:26).
- You are viewing the most recent version of this article.
Author Disclosures
- Judith Breuer, MD,
- Maud Pacou, BSc,
- Aline Gauthier, BSc and
- Martin M. Brown, MD
- Judith Breuer, MD,
NONE
NONE
NONE
NONE
application of targeted enrichment technology to wholeviral genome sequencingNovel method which allows recovery of sufficient viralnucleic acid for whole genome sequencing from clinical samples
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Medical Research Council UK G0700814 Reverse genetics tomap determinants of VZV Oka strain attenuation andvirulence. (PI) March 2008-Feb 2012
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Maud Pacou, BSc,
NONE
NONE
NONE
NONE
NONE
NONE
(1) Amaris (consultancy company), position: Statistical Analyst, since 2009
(1) Part of the Amaris project team who acted as a consultancy company for the UCL
NONE
NONE
NONE
(1) Perceived remuneration from Amaris as an employee of this company
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Acted as a consultant to advise on the implementation and interpretation of studies related to epidemiology and statistics in my function of statistical analyst at Amaris
- Aline Gauthier, BSc and
NONE
NONE
NONE
NONE
NONE
NONE
Amaris,consultancy company, position:Director, 4 years
Part of the Amaris project team, who acted as a consultant for the University College of London (UCL)
NONE
NONE
NONE
Perceived remuneration from Amaris as an employee of this company
NONE
NONE
NONE
As serving on the board of directors of Amaris UK
NONE
NONE
NONE
NONE
Acted as a consultant/expert to advise on the implementation and interpretation of studies related to epidemiology, health economics and statistics in my function of director of Amaris
- Martin M. Brown, MD
(1) I received compensation from Bayer Healthcare for the work and travel required as a member of a Data Safety Monitoring Board(2) I received compensation from St Jude Medical for work and travel required as Chairman of a trial Clinical Events Committee(3) I received compensation from Baxter Innovations for for the work and travel required as a member of a for the work and travel required as a member of a Clinical Advisory Board
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) National Institute for Health Research, PB-PG-0609-19216, funding for the Second European Carotid Surgery Trial (ECST-2), 2012-2014
NONE
(1) UCL receives funding for research on carotid stenosis from CORDA(2) MMB's Chair in Stroke Medicine at UCL is supported by the Reta Lila Weston Trust for Medical Research
NONE
NONE
NONE
NONE
NONE
NONE
- From the Division of Infection and Immunity (J.B.), and Institute of Neurology (M.M.B.), University College London; and Amaris (M.P., A.G.).
- Correspondence to Dr. Breuer: j.breuer{at}ucl.ac.uk
Article usage
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
More Online
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Related Articles
Topics Discussed
Alert Me
Recommended articles
-
Corrected and Republished Articles
Herpes zoster as a risk factor for stroke and TIAA retrospective cohort study in the UKJudith Breuer, Maud Pacou, Aline Gautier et al.Neurology, July 07, 2014 -
Articles
Herpes zoster ophthalmicus and the risk of strokeA population-based follow-up studyHerng-Ching Lin, Ching-Wen Chien, Jau-Der Ho et al.Neurology, March 03, 2010 -
Articles
The varicella zoster virus vasculopathiesClinical, CSF, imaging, and virologic featuresM. A. Nagel, R. J. Cohrs, R. Mahalingam et al.Neurology, March 10, 2008 -
Articles
The value of detecting anti-VZV IgG antibody in CSF to diagnose VZV vasculopathyM. A. Nagel, B. Forghani, R. Mahalingam et al.Neurology, February 07, 2007